肺移植中的噬菌体治疗:现状与未来可能
本文总结肺移植中噬菌体治疗的现状。噬菌体治疗已在部分肺移植候选者和受者中以同情用药方式使用,主要针对多重耐药革兰阴性菌和非典型分枝杆菌感染,并显示出临床安全性。噬菌体生物分布、免疫相互作用及临床试验现况被讨论,需针对这一脆弱人群设计良好临床试验。
要点
- 噬菌体治疗已在肺移植候选者和受者中同情用药,主要针对多重耐药革兰阴性菌和非典型分枝杆菌感染,显示临床安全性。
- 部分噬菌体治疗病例出现血清中和,临床影响似乎可变。
- 目前临床试验未专门针对肺移植候选者或受者,需设计良好临床试验。
核心结论
- 噬菌体治疗在肺移植中已以同情用药方式使用并显示临床安全性,但需针对这一脆弱人群设计良好的临床试验。
研究设计与样本
- 本文为综述,总结肺移植中噬菌体治疗的现有知识。
主要发现
- 噬菌体治疗已在若干肺移植候选者和受者中以同情用药方式使用,主要针对多重耐药革兰阴性菌感染和非典型分枝杆菌感染,并显示出临床安全性。
- 静脉或雾化给药后噬菌体生物分布尚未被广泛研究,但本文呈现了初步数据。
- 噬菌体与固有免疫和适应性免疫系统相互作用;现有文献显示部分噬菌体治疗病例出现血清中和,尽管临床影响似乎可变。
- 本文总结了涉及慢性肺病患者的当前临床试验,但没有一项专门针对肺移植候选者或受者。
临床怎么用
- 除治疗活动性感染外,多种临床场景可能受益于噬菌体治疗:移植前或移植期间针对多重耐药菌定植使用噬菌体,可能使目前被许多中心拒绝的候选者进入等待名单,并可能降低等待名单死亡率和移植后感染。
- 噬菌体可用于生物膜相关的支气管支架感染。
- 噬菌体使用可能影响同种异体移植物功能和慢性排斥反应。
局限性
- 静脉或雾化给药后噬菌体生物分布尚未被广泛研究。
- 当前临床试验没有一项专门针对肺移植候选者或受者。
- 需要针对这一脆弱患者人群设计良好的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with chronic lung disease and lung transplantation have high rates of colonization and infection from multidrug-resistant (MDR) organisms. This article summarizes the current state of knowledge regarding phage therapy in the setting of lung transplantation. Phage therapy has been used in several lung transplant candidates and recipients on a compassionate use basis targeting mostly MDR gram-negative infections and atypical mycobacterial infections with demonstrated clinical safety. Phage biodistribution given intravenously or via nebulization has not been extensively studied, though preliminary data are presented. Phage interacts with both the innate and adaptive immune system; current literature demonstrates the development of serum neutralization in some cases of phage therapy, although the clinical impact seems variable. A summary of current clinical trials involving patients with chronic lung disease is presented, though none are specifically targeting lung transplant candidates or recipients. In addition to treatment of active infections, a variety of clinical scenarios may benefit from phage therapy, and well-designed clinical trials involving this vulnerable patient population are needed: pre- or peritransplantation use of phage in the setting of MDR organism colonization may lead to waitlisting of candidates currently declined by many centers, along with potential reduction of waitlist mortality rates and posttransplant infections; phage may be used for biofilm-related bronchial stent infections; and, finally, there is a possibility that phage use can affect allograft function and chronic rejection.
引用
- Aslam S. Phage Therapy in Lung Transplantation: Current Status and Future Possibilities. Clin Infect Dis. 2023. PMID: 37932113. doi:10.1093/cid/ciad528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。